Alx Oncology Holdings (ALXO) - Total Assets
Based on the latest financial reports, Alx Oncology Holdings (ALXO) holds total assets worth $178.33 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Alx Oncology Holdings debt service capacity to assess how comfortably operating cash covers total debt obligations.
Alx Oncology Holdings - Total Assets Trend (2018–2025)
This chart illustrates how Alx Oncology Holdings 's total assets have evolved over time, based on quarterly financial data. See ALXO book value for net asset value and shareholders' equity analysis.
Alx Oncology Holdings - Asset Composition Analysis
Current Asset Composition (December 2025)
Alx Oncology Holdings 's total assets of $178.33 Million consist of 85.9% current assets and 14.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 27.7% |
| Accounts Receivable | $298.00K | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Alx Oncology Holdings 's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ALXO market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alx Oncology Holdings 's current assets represent 85.9% of total assets in 2025, a decrease from 91.4% in 2018.
- Cash Position: Cash and equivalents constituted 27.7% of total assets in 2025, down from 74.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
Alx Oncology Holdings Competitors by Total Assets
Key competitors of Alx Oncology Holdings based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
Alx Oncology Holdings - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.21 | 5.47 | 29.49 |
| Quick Ratio | 7.21 | 5.47 | 29.49 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $125.39 Million | $83.79 Million | $398.30 Million |
Alx Oncology Holdings - Advanced Valuation Insights
This section examines the relationship between Alx Oncology Holdings 's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.38 |
| Latest Market Cap to Assets Ratio | 3.51 |
| Asset Growth Rate (YoY) | -60.0% |
| Total Assets | $59.05 Million |
| Market Capitalization | $207.23 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Alx Oncology Holdings 's assets at a significant premium (3.51x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Alx Oncology Holdings 's assets decreased by 60.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Alx Oncology Holdings (2018–2025)
The table below shows the annual total assets of Alx Oncology Holdings from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $59.05 Million | -60.04% |
| 2024-12-31 | $147.78 Million | -39.08% |
| 2023-12-31 | $242.55 Million | -20.86% |
| 2022-12-31 | $306.49 Million | -19.38% |
| 2021-12-31 | $380.18 Million | -12.81% |
| 2020-12-31 | $436.05 Million | +3984.43% |
| 2019-12-31 | $10.68 Million | -4.37% |
| 2018-12-31 | $11.16 Million | -- |
About Alx Oncology Holdings
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collabora… Read more